
    
      With protocol amendment 08 (13-Nov-2019), once study participants have achieved the study
      objective or the study has ended, participants will be discontinued from this study and may
      be enrolled in a pembrolizumab extension study (NCT03486873) to continue protocol-defined
      assessments and treatment.
    
  